Drug Profile
Research programme: protein kinase inhibitors - Millennium/Viracta Therapeutics/Supernus
Alternative Names: BIIB 024; SNS 229Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Biogen Idec; Sunesis Pharmaceuticals
- Developer Takeda Oncology; Viracta Therapeutics
- Class Pyrazines; Small molecules; Thiazoles
- Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Protein kinase inhibitors; Proto oncogene protein b raf inhibitors; Raf kinase inhibitors; Ras signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 08 Nov 2017 Preclinical development is ongoing in USA